SGR-1505 is under clinical development by Schrodinger and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase I drugs for Mantle Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SGR-1505’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SGR-1505 overview

SDGR-3 is under development for the treatment of BTK-resistant or relapsed B-cell non-Hodgkin lymphoma, diffuse large b-cell lymphoma, chronic lymphocytic leukemia and mantle cell lymphoma (MCL). It is administered through oral route. It acts by oncogenic activation of nuclear factor-kappa B which acts by targeting MALT1 activity. MALT1 is the mucosa-associated lymphoid tissue lymphoma translocation gene 1 which plays an important role in NF-kappaB activation. MALT1 enzymatic activity is implicated in the development of inflammatory, autoimmune disorders and lymphomas. It is developed based on the Schrodinger artificial intelligence (AI) technology.

Schrodinger overview

Schrodinger is a technology company that provides software solutions for drug discovery. The company offers a computational platform designed with predictive modeling, data analytics and collaboration applicable to molecular discovery. Its pipeline includes SGR-1505 (MALT1) against non-Hodgkin’s lymphoma, SGR-2921 (CDC7) to treat hematological cancers and solid tumors and SGR-3515 (Wee1) for gynecological cancers LRRK2 for Neurology and SOS1 / KRAS for cancers. Schrodinger‘s other products include small molecule products, biological drug discovery and material science products. It provides training, documentation and support services. The company operates in the US, Germany, Japan, Ireland, the UK, India and South Korea. Schrodinger is headquartered in New York, the US.

For a complete picture of SGR-1505’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.